Communication Dans Un Congrès Année : 2024

Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Domaines

Fichier non déposé

Dates et versions

hal-04966067 , version 1 (25-02-2025)

Identifiants

  • HAL Id : hal-04966067 , version 1

Citer

Olivier Trédan. Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium 2024, Dec 2024, San Antonio (TX), United States. ⟨hal-04966067⟩
28 Consultations
0 Téléchargements

Partager

  • More